ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

STX Shield Therapeutics Plc

2.40
0.00 (0.00%)
24 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Shield Therapeutics Plc LSE:STX London Ordinary Share GB00BYV81293 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.40 2.30 2.50 2.40 2.20 2.35 3,366,745 11:37:33
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 4.47M -40.44M -0.0522 -0.46 18.61M
Shield Therapeutics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker STX. The last closing price for Shield Therapeutics was 2.40p. Over the last year, Shield Therapeutics shares have traded in a share price range of 1.075p to 12.75p.

Shield Therapeutics currently has 775,429,360 shares in issue. The market capitalisation of Shield Therapeutics is £18.61 million. Shield Therapeutics has a price to earnings ratio (PE ratio) of -0.46.

Shield Therapeutics Share Discussion Threads

Showing 5076 to 5096 of 23350 messages
Chat Pages: Latest  214  213  212  211  210  209  208  207  206  205  204  203  Older
DateSubjectAuthorDiscuss
29/1/2020
15:40
Sorry I am on holidays Asia, with various distractions of a pleasant kind.

All seems fine to me, not selling any, added a few recently, nothing more to do.

Just attending to some other little gems in the making such as PPS & ITX, imo

Catch up in a few weeks, off to Vietnam, face mask to the ready

ny boy
29/1/2020
10:11
Can you copy and post it nyboy ?
Cheers

peachie 74
28/1/2020
14:03
Hardman & Co Research note out today , basically says STX is at an exciting juncture, awaiting news on the US distribution partner deal, the next value inflection point.

Basically sit back and relax, as most of us have been over the last year.

ny boy
28/1/2020
11:17
I will be looking at adding further this week along with a couple of other Bio's(NFX and HEMO) as the sector will be a strong gainer with anticipated market volatility.
galaxy enforcer
27/1/2020
22:57
It seems fairly obvious through well informed posts by nyboy, etc that this share price will probably be a big earner for those investors with the patience to set out the next few months. A conservative estimate of £4-5 pounds should be easily achieved by the middle of the year. Sales and revenue will increase steadily and by this time next year all will be well. Thank you for your guidance to a rookie investor.
maximus72
27/1/2020
20:36
In my opinion the recent drop was down to people exiting prior to the TU in case of any surprise. As mentioned earlier now that we have clarity there is no reason as to why the price should not recover whilst we await the US deal to be announced.
galaxy enforcer
27/1/2020
19:53
I think the share price held up pretty well today considering that revenue was slightly lower than expected (and the general bloodbath today). Given the chunky buys that came through, the price should arguably have been slightly up rather than slightly down.
secret investor
27/1/2020
13:10
The concern with the constant share price erosion is that by the time the deal info comes out the price will only rebound to previous levels.

The daily tick down on this is frustrating

lako42
27/1/2020
10:51
STX is usually a safe haven for investors during times of general global market uncertainty..ie. like right now.

As hS been for a long time HOLD, awaiting US commercialization deal, I am sure will come in this quarter. GLA

ny boy
27/1/2020
10:23
No cobwebs in that TU. News expected regarding the US soon. Should see this back at £2 without any problem when that happens.
galaxy enforcer
27/1/2020
07:52
Sorry I think I might have miss read the update. It’s mostly milestone payments not sales.
crankyman
27/1/2020
07:37
Had a quick glimpse but having Thai lunch, which is distracting as it’s very tasty indeed

All seems good on the cash front until 2021, so just awaiting the US commercialization deal, I guess negotiations take time, at least the prospective partner can’t screw them on terms now their cash position is solid until 2021

ny boy
27/1/2020
07:34
European market access is probably limited to 100 million people at 1/3 the expected US price. Consider multiplying this number by 9 and you have something the US could achieve.
crankyman
27/1/2020
07:31
Should stop the share price dropping further.
rafboy
27/1/2020
07:19
It’s near £12 million in sales in the effective launch year in two markets where U.K. access would be limited to probably less than half the country. I think it’s pretty OK.
crankyman
27/1/2020
07:19
All positive as I look at it.
peachie 74
27/1/2020
07:16
This could help reduce uncertainty for the US partner(s)
crankyman
27/1/2020
07:15
Thoughts ? Reads well albeit pretty much in line with expectations. I think the wording on “looking forward “ to updating on us deals is positive. The eu sales looks a bit lacklustre .
2theduke
27/1/2020
07:14
European sales growing at around a constant rate. Growth not slowing not increasing for the moment. Need those other markets to come on stream but looks good.
crankyman
27/1/2020
07:08
Trading updated posted
crankyman
25/1/2020
18:48
Thanks guys.
Nyboy - I’m looking at renx, I see a comment you made last year about looking at it. What were your final thoughts ? Thanks

2theduke
Chat Pages: Latest  214  213  212  211  210  209  208  207  206  205  204  203  Older

Your Recent History

Delayed Upgrade Clock